A comprehensive meta-analysis on safety outcomes reveals the novel potentials of SGLT2is, especially preventing respiratory diseases

Front Endocrinol (Lausanne). 2024 Apr 29:15:1376446. doi: 10.3389/fendo.2024.1376446. eCollection 2024.

Authors

YuJun Cai¹, HaiTao Zou¹, Rong Hu¹, Hao Chen¹, GuoHuan Yang¹, LiDan Gong²

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Dianjiang People's Hospital of Chongqing, Chongqing, China.
² Department of Pharmacy, Dianjiang People's Hospital of Chongqing, Chongqing, China.

No abstract available

Keywords: NSCLC; SGLT2is; anemia; back pain; gastrointestinal diseases; respiratory diseases.

Publication types

Meta-Analysis

MeSH terms

Diabetes Mellitus, Type 2 / prevention & control
Humans
Hypoglycemic Agents / therapeutic use
Respiration Disorders / epidemiology
Respiration Disorders / prevention & control
Respiratory Tract Diseases / prevention & control
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.